2023
Pediatric HIV Disclosure Intervention Improves Immunologic Outcome at 48 Weeks: The Sankofa Trial Experience
Shabanova V, Emuren L, Gan G, Antwi S, Renner L, Amissah K, Kusah J, Lartey M, Reynolds N, Paintsil E. Pediatric HIV Disclosure Intervention Improves Immunologic Outcome at 48 Weeks: The Sankofa Trial Experience. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2023, 94: 371-380. PMID: 37643414, PMCID: PMC10617661, DOI: 10.1097/qai.0000000000003292.Peer-Reviewed Original ResearchConceptsHIV disclosure interventionsVirologic outcomesCD4 percentWeek 48HIV statusIntervention groupHIV disclosureDisclosure interventionDetectable viral loadWorld Health OrganizationAntiretroviral therapyImmunologic outcomesClinical outcomesIntervention armViral loadControl armClinical trialsTrial experienceSecondary analysisDisclosure statusHealth OrganizationCategorical variablesWeeksLinear mixed modelsBaseline
2022
Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics
Edelman EJ, Gan G, Dziura J, Esserman D, Porter E, Becker WC, Chan PA, Cornman DH, Helfrich CD, Reynolds J, Yager JE, Morford KL, Muvvala SB, Fiellin DA. Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics. JAMA Network Open 2022, 5: e2236904. PMID: 36251291, PMCID: PMC9577676, DOI: 10.1001/jamanetworkopen.2022.36904.Peer-Reviewed Original ResearchConceptsTobacco use disorderHIV clinicOpioid use disorderUse disordersAlcohol use disorderAddiction treatmentControl periodImplementation facilitationAdoption of medicationsMulticomponent implementation strategyProvision of MOUDUS HIV clinicsMaintenance periodElectronic health record dataHealth record dataEvaluation periodAdult patientsMean ageClinical trialsMAIN OUTCOMEClinicMOUDPatientsDisordersPatient incentivesDevelopment and Initial Validation of a Novel System to Assess Ichthyosis Severity
Sun Q, Asch S, Bayart C, Bayliss SJ, Benjamin L, Bruckner A, DiGiovanna JJ, Fleckman P, Funk T, Lucky A, Nelson CA, Newell B, Polcari I, Teng J, Williams ML, Gan G, Deng Y, Paller AS, Choate KA. Development and Initial Validation of a Novel System to Assess Ichthyosis Severity. JAMA Dermatology 2022, 158: 359-365. PMID: 35171201, PMCID: PMC8851366, DOI: 10.1001/jamadermatol.2021.5917.Peer-Reviewed Original ResearchConceptsIchthyosis severityIntraclass correlation coefficientIntrarater reliabilityCare of patientsQuantifying treatment outcomesPatient advocacy groupsMost body sitesGood interrater reliabilityReferral centerDisease burdenClinical trialsTreatment outcomesErythema scoreMAIN OUTCOMEQualitative studyScoring systemBody sitesSeverityInterrater reliabilityUser-friendly instrumentErythemaPhotographs of participantsCohortDermatologistsEntire body
2021
Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias
Branagan AR, Duffy E, Gan G, Li F, Foster C, Verma R, Zhang L, Parker TL, Seropian S, Cooper DL, Brandt D, Kortmansky J, Witt D, Ferencz TM, Dhodapkar KM, Dhodapkar MV. Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias. Blood Advances 2021, 5: 1535-1539. PMID: 33683337, PMCID: PMC7948269, DOI: 10.1182/bloodadvances.2020003880.Peer-Reviewed Original ResearchConceptsHigh-dose influenza vaccinationPlasma cell dyscrasiaInfluenza vaccinationProtective immunityCell dyscrasiaPCD patientsPlacebo-controlled clinical trialHigh-dose vaccinationHigh-dose vaccineInfluenza-specific immunityBurden of influenzaSaline placebo injectionsAge-based vaccinationHigher seroprotectionSerologic immunityPlacebo injectionsVaccine strategiesTiter responseClinical trialsFlu seasonPatientsVaccinationImmunityNovel coronavirusSeroprotection
2016
Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial
Branagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Zelterman D, Gan G, Brandt D, Kortmansky J, Witt D, Ferencz T, Dhodapkar M. Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial. Blood 2016, 128: 2139. DOI: 10.1182/blood.v128.22.2139.2139.Peer-Reviewed Original ResearchHigh-dose influenza vaccinePlasma cell disordersInfluenza vaccinationCell-mediated immunityInfluenza vaccineInfluenza infectionCell disordersClinical correlatesVaccination strategiesPCD patientsRandomized studySingle vaccineClinical trialsDose seriesFlu seasonInfection rateHigh-dose influenza vaccinationLaboratory-confirmed influenza infectionTwo-dose vaccination strategyHigh-dose vaccinationHigh-dose vaccineInfluenza vaccination strategiesPresent randomized studySerologic response rateSeasonal influenza vaccination